Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
HTG Molecular Diagnostics Reports Second Quarter 2018 Results
August 7, 2018 at 4:05 PM EDT
PDF Version
Revenue increased 179% and 190%, respectively, compared to the three and six-month periods in the prior year
https://htgmolecular.gcs-web.com/news-releases/news-release-details/htg-molecular-diagnostics-reports-second-quarter-2018-results
HTG Molecular Diagnostics Reports Second Quarter 2018 Results
August 7, 2018 at 4:05 PM EDT
PDF Version
Revenue increased 179% and 190%, respectively, compared to the three and six-month periods in the prior year
Call scheduled for today, August 7, at 4:30 pm ET
TUCSON, Ariz., Aug. 07, 2018 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a provider of instruments, reagents and services for molecular profiling applications, today reported financial results for the three and six-month periods ended June 30, 2018.
Recent Accomplishments & Highlights:
Achieved revenue of $4.9 million and $9.1 million for the three and six-month periods ended June 30, 2018, respectively, which represents a 179% and 190% increase over the respective periods in 2017.
Featured a new comprehensive Precision Immuno-Oncology panel quantifying expression of nearly 1,400 genes at the 2018 American Society of Clinical Oncology (ASCO) annual meeting, in preparation for an expected commercial launch this month. This panel is automated on the HTG EdgeSeq instrument and optimized for low sample input.
Executed a master agreement with Oncologie, Inc. (“Oncologie”) to partner on the development of biomarkers associated with Oncologie’s immuno-oncology drug development utilizing HTG’s assay development and VERI/O service lab capabilities. Oncologie has several later stage drugs in their pipeline and is dedicated to biomarker-driven clinical development for immuno-oncology.
Entered into a non-exclusive license and supply agreement with Firalis S.A. (“Firalis”) supporting potential commercialization of a theranostic test to predict rheumatoid arthritis patient response to anti-TNF a therapy. HTG will provide the instrumentation and reagent kits to support Firalis’s commercialization plans, expected to include both a central lab and distributed business model.
“The company continues to execute well against our 2018 objectives and longer-term strategies”, said TJ Johnson, Chief Executive Officer of HTG. “We are excited about the imminent launch of our new immuno-oncology panel, and other new panels planned for launch in Q4, and we believe we are gaining momentum from our recent investments into additional sales positions, which we expect to impact our results in the back half of the year.”
https://htgmolecular.gcs-web.com/news-releases/news-release-details/htg-molecular-diagnostics-reports-second-quarter-2018-results
Thank you. Have a nice day.
What does all that mean...bottom line please?
I can say for weeks that it’s gonna rain, it’s gonna be sunny, it’s gonna go up, it’s gonna go down. Eventually it happens. Tell me a specific day and time and then you know something.
Go find a chick!
VTLN NEWS!!!
Vet Online Supply $9M 2018 Projections
By GlobeNewswire, May 15, 2018, 08:30:00 AM EDT
Vote upAAA
KELSEYVILLE, CA., May 15, 2018 (GLOBE NEWSWIRE) -- Vet Online Supply, Inc. (OTC PINK:VTNL) (the Company), announces today that the company has filed its financial statements for the first quarter ending March 31, 2018.
Daniel Rushford, CEO and Chairman, stated "The Company has secured over $9M in purchase orders for 2018, with expected projected revenue of $1.5M for Q2 of 2018. We manufacture holistic certified CBD pet products that include treats, liquid drops, and concentrated oral sprays. With our first wholesale distribution contract and continued growing online retail sales, we expect to focus on paying down our debt while implementing anti-dilution programs, inclusive of the repurchase of shares and a severe reduction of the authorized/issued-outstanding shares."
Mr. Rutherford further stated, "Vet Online Supply continues to grow, and we are in a transitional period whereas we are complying with debt reserves for our note holders and preparing to reduce the authorized shares as well as the issued and outstanding shares. We anticipate reducing our notes in Q2 while at the same time repurchasing shares by utilizing our own revenue resources."
https://vetonlinesupplies.com/wp-content/uploads/2018/03/VTNL-Fact-Sheet-3-25-2018.pdf
www.vetonlinesupplies.com
ABOUT VET ONLINE SUPPLY:
Vet Online Supply Inc. The company manufactures its own brand of holistic pet products to promote health and well being. The goal of "Vet Online Supply" is to provide the $38B industry with value priced, superior quality holistic pet products.
Safe Harbor for Forward-Looking Statements: This news release includes forward-looking statements. While these statements are made to convey to the public the company's progress, business opportunities and growth prospects, readers are cautioned that such forward-looking statements represent management's opinion. Whereas management believes such representations to be true and accurate based on information and data available to the company at this time, actual results may differ materially from those described. The Company's operations and business prospects are always subject to risk and uncertainties. Important factors that may cause actual results to differ are and will be set forth in the company's periodic filings with the U.S. Securities and Exchange Commission.
Contact:
Vet Online Supply, Inc.Meridian Consulting
323-364-3793
Real Company!!!
https://vetonlinesupplies.com/
VTLN NEWS!!!
Vet Online Supply $9M 2018 Projections
By GlobeNewswire, May 15, 2018, 08:30:00 AM EDT
Vote upAAA
KELSEYVILLE, CA., May 15, 2018 (GLOBE NEWSWIRE) -- Vet Online Supply, Inc. (OTC PINK:VTNL) (the Company), announces today that the company has filed its financial statements for the first quarter ending March 31, 2018.
Daniel Rushford, CEO and Chairman, stated "The Company has secured over $9M in purchase orders for 2018, with expected projected revenue of $1.5M for Q2 of 2018. We manufacture holistic certified CBD pet products that include treats, liquid drops, and concentrated oral sprays. With our first wholesale distribution contract and continued growing online retail sales, we expect to focus on paying down our debt while implementing anti-dilution programs, inclusive of the repurchase of shares and a severe reduction of the authorized/issued-outstanding shares."
Mr. Rutherford further stated, "Vet Online Supply continues to grow, and we are in a transitional period whereas we are complying with debt reserves for our note holders and preparing to reduce the authorized shares as well as the issued and outstanding shares. We anticipate reducing our notes in Q2 while at the same time repurchasing shares by utilizing our own revenue resources."
https://vetonlinesupplies.com/wp-content/uploads/2018/03/VTNL-Fact-Sheet-3-25-2018.pdf
www.vetonlinesupplies.com
ABOUT VET ONLINE SUPPLY:
Vet Online Supply Inc. The company manufactures its own brand of holistic pet products to promote health and well being. The goal of "Vet Online Supply" is to provide the $38B industry with value priced, superior quality holistic pet products.
Safe Harbor for Forward-Looking Statements: This news release includes forward-looking statements. While these statements are made to convey to the public the company's progress, business opportunities and growth prospects, readers are cautioned that such forward-looking statements represent management's opinion. Whereas management believes such representations to be true and accurate based on information and data available to the company at this time, actual results may differ materially from those described. The Company's operations and business prospects are always subject to risk and uncertainties. Important factors that may cause actual results to differ are and will be set forth in the company's periodic filings with the U.S. Securities and Exchange Commission.
Contact:
Vet Online Supply, Inc.Meridian Consulting
323-364-3793
Real Company!!!
https://vetonlinesupplies.com/
VTLN is a very real company
https://vetonlinesupplies.com/
I’m totally confuse here... the last results seemed like great news.
Can you explain?
Maybe just some trickery ... this will go over $6. I answered myself. I’m hanging in here. Not only do i talk to myself but i chat in a chatroom to myself. Follow me at your risk! Either going to the moon or rehab!
Huh...Why the drop? I thought we would see $6 this morning. There is news of stock being a “buy”... yet it drops. Can you explain?
Sounds good. You see this hitting back over $10 this year?
I see... wow!
Why is this going down after hours?
HTGM - After Bell News...441% rev QoQ and 190% YoY. 2018 guidance increased as well... super growth!!
HTGM - After Bell News...441% rev QoQ and 190% YoY. 2018 guidance increased as well... insane growth!!
what does this mean or suppose to mean?
NEWS TODAY..Square Is One of 4 Upset Picks in Our Latest 'Sweet 16' Stock Selections
By REAL MONEY Follow | MAR 20, 2018 | 12:30 PM EDT
inShare
Email Email
Print Print
Stock quotes in this article: HTGM, MRK, ILMN, QGEN, RTEC, DECK, SQ, TWTR
Is your bracket busted after all the upsets in the first two rounds of the NCAA men's basketball tournament?
Let's pick stocks instead.
In honor of the most exciting three weeks in sports, Real Money presents its own "Sweet 16." Four great stock picks and trades each day this week from our columnists leading up to Thursday's games.
We tipped it off Monday with the "East Region."
Now we are unveiling the "South Region," with several underdog selections primed for more upsets.
James "Rev Shark" DePorre: HTG Molecular Diagnostics (HTGM)
My pick for the Real Money Sweet 16 is HTG Molecular Diagnostics, a small biotechnology company that focuses on molecular profiling and delivery mechanisms rather than in-house drug development. HTGM works with major companies like Merck (MRK) , Illumina (ILMN) and Qiagen (QGEN) .
On Jan. 4, 2018, the company issued upside guidance for the fourth quarter of 2017 of $6.9 million to $7.2 million versus guidance from two analysts of $3.45 million. It increased guidance for the entire year of 2018 to $20 million-$25 million versus analyst estimates of $13.93 million.
Technically, the chart of HTGM is developing well and I'm looking for a breakout over the $5.50 level to propel it higher.
HTGM is undersized but it should make up for its small stature with speed and flexibility. Watch for HTGM to upset some big-cap names.
https://realmoney.thestreet.com/articles/03/20/2018/square-one-4-upset-picks-our-latest-sweet-16-stock-selections?puc=cnnmoneyp&cm_ven=CNNMONEYP
NEWS TODAY..Square Is One of 4 Upset Picks in Our Latest 'Sweet 16' Stock Selections
By REAL MONEY Follow | MAR 20, 2018 | 12:30 PM EDT
inShare
Email Email
Print Print
Stock quotes in this article: HTGM, MRK, ILMN, QGEN, RTEC, DECK, SQ, TWTR
Is your bracket busted after all the upsets in the first two rounds of the NCAA men's basketball tournament?
Let's pick stocks instead.
In honor of the most exciting three weeks in sports, Real Money presents its own "Sweet 16." Four great stock picks and trades each day this week from our columnists leading up to Thursday's games.
We tipped it off Monday with the "East Region."
Now we are unveiling the "South Region," with several underdog selections primed for more upsets.
James "Rev Shark" DePorre: HTG Molecular Diagnostics (HTGM)
My pick for the Real Money Sweet 16 is HTG Molecular Diagnostics, a small biotechnology company that focuses on molecular profiling and delivery mechanisms rather than in-house drug development. HTGM works with major companies like Merck (MRK) , Illumina (ILMN) and Qiagen (QGEN) .
On Jan. 4, 2018, the company issued upside guidance for the fourth quarter of 2017 of $6.9 million to $7.2 million versus guidance from two analysts of $3.45 million. It increased guidance for the entire year of 2018 to $20 million-$25 million versus analyst estimates of $13.93 million.
Technically, the chart of HTGM is developing well and I'm looking for a breakout over the $5.50 level to propel it higher.
HTGM is undersized but it should make up for its small stature with speed and flexibility. Watch for HTGM to upset some big-cap names.
https://realmoney.thestreet.com/articles/03/20/2018/square-one-4-upset-picks-our-latest-sweet-16-stock-selections?puc=cnnmoneyp&cm_ven=CNNMONEYP
NEWS TODAY..Square Is One of 4 Upset Picks in Our Latest 'Sweet 16' Stock Selections
By REAL MONEY Follow | MAR 20, 2018 | 12:30 PM EDT
inShare
Email Email
Print Print
Stock quotes in this article: HTGM, MRK, ILMN, QGEN, RTEC, DECK, SQ, TWTR
Is your bracket busted after all the upsets in the first two rounds of the NCAA men's basketball tournament?
Let's pick stocks instead.
In honor of the most exciting three weeks in sports, Real Money presents its own "Sweet 16." Four great stock picks and trades each day this week from our columnists leading up to Thursday's games.
We tipped it off Monday with the "East Region."
Now we are unveiling the "South Region," with several underdog selections primed for more upsets.
James "Rev Shark" DePorre: HTG Molecular Diagnostics (HTGM)
My pick for the Real Money Sweet 16 is HTG Molecular Diagnostics, a small biotechnology company that focuses on molecular profiling and delivery mechanisms rather than in-house drug development. HTGM works with major companies like Merck (MRK) , Illumina (ILMN) and Qiagen (QGEN) .
On Jan. 4, 2018, the company issued upside guidance for the fourth quarter of 2017 of $6.9 million to $7.2 million versus guidance from two analysts of $3.45 million. It increased guidance for the entire year of 2018 to $20 million-$25 million versus analyst estimates of $13.93 million.
Technically, the chart of HTGM is developing well and I'm looking for a breakout over the $5.50 level to propel it higher.
HTGM is undersized but it should make up for its small stature with speed and flexibility. Watch for HTGM to upset some big-cap names.
https://realmoney.thestreet.com/articles/03/20/2018/square-one-4-upset-picks-our-latest-sweet-16-stock-selections?puc=cnnmoneyp&cm_ven=CNNMONEYP
PAST PR's links...Next PR will be $$$
http://www.keyc.com/story/37565775/vet-online-supply-new-oral-spray-products-for-big-box-pet-stores
https://globenewswire.com/news-release/2018/03/13/1421302/0/en/Vet-Online-Supply-Introduces-Oral-CBD-Sprays-for-Pets.html
https://vetonlinesupplies.com/product/cbd-pet-supplement-drops/
Next PR will be $$$$
Vet Online Supply Introduces Oral CBD Sprays for Pets
https://globenewswire.com/news-release/2018/03/13/1421302/0/en/Vet-Online-Supply-Introduces-Oral-CBD-Sprays-for-Pets.html
Thank you.
I appreciate ALL the kind words and honesty. Hearing others saying they too took a L is not my wish though. I HOPE WE ALL MAKE BIG MONEY! I will say that the honest replies to my sadness today has gave me hope. The world is not all bad and the internet can be kind. Have a great evening all!
Goodtimes79...you really believe a PR will bring this back or better yet, there's one coming? No PR needed. We just need Jesus! I'm going to bible study tonight. I'm not ready to drive my car off a cliff, at least not with me in it. I'm just facing my truth. My truth is making money on wall street is much harder than making out with several of my neighbors.
BMIC is at .0020 for whatever this means. Who the hell is BMIC and why is he important?
Am i the only one dying over here or am i just dead already? What a life. I have nothing going right. I use to think so highly of myself, it was brief. I take one step forward only to take 5 backward steps. I am the BIGGEST loser.
I bought several times and each time, the price went lower. My first name is BIG and last name IDIOT.
Will I come back to life?
Hate today more than yesterday!
I have not sold my 40M yet. HOLD!!!
I’m out...50% Loss. Good luck all!
I’m here and i’m still acting like a lil girl!!!!
There's blood in the streets, water and air..BUY!!!!
Is it a good time to buy, honestly?
I'm in opening bell... i don't hope for a pullback. I rather it soar to copper! LETS GO VTNL!!! THIS IS THE REAL DEAL!